Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

IgA Vasculitis: Influence of CD40, BLK and BANK1 Gene Polymorphisms

  • Batista-Liz, Joao Carlos
  • Genre, Fernanda
  • Pulito-Cueto, Verónica
  • Remuzgo-Martínez, Sara
  • Prieto-Peña, Diana
  • Márquez, Ana
  • Ortego-Centeno, Norberto
  • Leonardo, María Teresa
  • Peñalba, Ana
  • Narváez, Javier
  • Martín-Penagos, Luis
  • Belmar-Vega, Lara
  • Gómez Fernández, Cristina
  • Miranda-Filloy, J. A.
  • Caminal-Montero, Luis
  • Collado, Paz
  • Árgila, Diego de
  • Quiroga, Patricia
  • Vicente, Esther
  • Triguero-Martínez, Ana
  • Rubio, Esteban
  • León Luque, Manuel
  • Blanco-Madrigal, Juan María
  • Galíndez-Agirregoikoa, E.
  • Martín, Javier
  • Gualillo, Oreste
  • Blanco, Ricardo
  • Castañeda, Santos
  • González-Gay, Miguel A.
  • López-Mejías, Raquel
CD40, BLK and BANK1 genes involved in the development and signaling of B-cells are identified as susceptibility loci for numerous inflammatory diseases. Accordingly, we assessed the potential influence of CD40, BLK and BANK1 on the pathogenesis of immunoglobulin-A vasculitis (IgAV), predominantly a B-lymphocyte inflammatory condition. Three genetic variants within CD40 (rs1883832, rs1535045, rs4813003) and BLK (rs2254546, rs2736340, rs2618476) as well as two BANK1 polymorphisms (rs10516487, rs3733197), previously associated with inflammatory diseases, were genotyped in 382 Caucasian patients with IgAV and 955 sex- and ethnically matched healthy controls. No statistically significant differences were observed in the genotype and allele frequencies of CD40, BLK and BANK1 when IgAV patients and healthy controls were compared. Similar results were found when CD40, BLK and BANK1 genotypes or alleles frequencies were compared between patients with IgAV stratified according to the age at disease onset or to the presence/absence of gastrointestinal or renal manifestations. Moreover, no CD40, BLK and BANK1 haplotype differences were disclosed between patients with IgAV and healthy controls and between patients with IgAV stratified according to the clinical characteristics mentioned above. Our findings indicate that CD40, BLK and BANK1 do not contribute to the genetic background of IgAV., This study was supported by European Union FEDER funds and “Fondo de Investigaciones Sanitarias” (grants PI18/00042 and PI21/00042) from “Instituto de Salud Carlos III” (ISCIII, Health Ministry, Spain). D.P.-P. is a recipient of a Río Hortega program fellowship from the ISCIII, co-funded by the European Social Fund (ESF, “Investing in your future”) (grant number CM20/00006). F.G. is supported by funds of the RICORS Program from ISCIII, co-funded by the European Union (grant number RD21/0002/0025). V.P.-C. is supported by funds of PI18/00042. S.R.-M. is supported by funds of the RETICS Program (RD16/0012/0009) (ISCIII, co-funded by the European Regional Development Fund (ERDF)). O.G. is a staff member of Xunta de Galicia (Servizo Galego de Saude (SERGAS)) through a research-staff stabilization contract (ISCIII/SERGAS) and his work is funded by ISCIII and the European Union FEDER fund (grant numbers RD16/0012/0014 (RIER) and PI17/00409). He is a beneficiary of project funds from the Research Executive Agency (REA) of the European Union in the framework of MSCA-RISE Action of the H2020 Program, project 734899—Olive-Net. R.L.-M. is a recipient of a Miguel Servet type II program fellowship from the ISCIII, co-funded by ESF (“Investing in your future”) (grant number CPII21/00004)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Role of VEGF Polymorphisms in the Susceptibility and Severity of Interstitial Lung Disease

  • Remuzgo-Martínez, Sara
  • Genre, Fernanda
  • Pulito-Cueto, Verónica
  • Atienza-Mateo, Belén
  • Mora Cuesta, Víctor Manuel
  • Iturbe Fernández, David
  • Berastegui Garcia, Cristina
Biomarker; Interstitial lung disease; Vascular endothelial growth factor, Biomarcador; Malaltia pulmonar intersticial; Factor de creixement endotelial vascular, Biomarcador; Enfermedad pulmonar intersticial; Factor de crecimiento vascular endotelial, The search for biomarkers that can help to establish an early diagnosis and prognosis of interstitial lung disease (ILD) is of potential interest. VEGF polymorphisms have been implicated in the development of several lung disorders. Consequently, we assessed, for the first time, the role of VEGF polymorphisms in the susceptibility and severity of ILD. A total of 436 Caucasian ILD patients (244 with idiopathic interstitial pneumonias (IIPs) and 192 with non-IIP) and 536 ethnically-matched healthy controls were genotyped for VEGF rs833061, rs1570360, rs2010963, rs3025020, and rs3025039 polymorphisms by TaqMan assays. Pulmonary function tests were collected from all the patients. VEGF serum levels were determined by ELISA in a subgroup of patients. No VEGF genotype, allele, carrier, or haplotype differences were found between ILD patients and controls as well as between IIP and non-IIP patients. However, an association of rs1570360 with IIP in women and also with lung function in IIP patients was found. None of the VEGF polymorphisms were associated with VEGF levels. In conclusion, our results suggest that VEGF does not seem to play a relevant role in ILD, although rs1570360 may influence the severity of ILD in women and a worse outcome in IIP patients., This research was partially supported by a grant from Spanish Society of Pulmonology and Thoracic Surgery (SEPAR 474-2017). S.R.-M. was supported by funds of the RETICS Program (RD16/0012/0009) from the “Instituto de Salud Carlos III” (ISCIII), co-funded by the European Regional Development Fund. V.P.-C. was supported by a pre-doctoral grant from IDIVAL (PREVAL 18/01). B.A.-M. was recipient of a “López Albo” post-residency program funded by Servicio Cántabro de Salud. L.L.-G. was supported by funds from IDIVAL (INNVAL 20/06). O.G. was beneficiary of a grant funded by Xunta de Galicia, Consellería de Educación, Universidade e Formación Profesional and Consellería de Economía, Emprego e Industria (GAIN), GPC IN607B2019/10. R.L.-M. was a recipient of a Miguel Servet type I program fellowship from the ISCIII, co-funded by the ESF, “Investing in your future” (grant CP16/00033).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Influence of MUC5B gene on antisynthetase syndrome

  • López-Mejías, Raquel|||0000-0003-0548-2689
  • Remuzgo-Martínez, Sara|||0000-0003-4455-7241
  • Genre, Fernanda|||0000-0003-3612-1448
  • Pulito-Cueto, Verónica|||0000-0002-3534-8467
  • Fernández Rozas, Sonia María
  • Llorca, Javier|||0000-0001-8569-861X
  • Iturbe, David|||0000-0002-5241-266X
  • Mora Cuesta, Víctor Manuel|||0000-0002-8161-0462
  • Ortego-Centeno, Norberto|||0000-0003-2325-0937
  • Gómez, Nair Pérez
  • Mera-Varela, Antonio
  • Martínez Barrio, Julia
  • López Longo, Francisco Javier
  • Mijares, Verónica
  • Lera-Gómez, Leticia
  • Usetti, María Piedad
  • Laporta, Rosalía
  • Pérez González, Virginia Luz
  • Gafas, Alicia De Pablo
  • Alfranca González, María Aránzazu
  • Calvo Alén, Jaime|||0000-0001-9378-8412
  • Romero-Bueno, Fredeswinda
  • Sánchez Pernaute, Olga
  • Nuno, Laura
  • Bonilla, Gema
  • Balsa, Alejandro|||0000-0001-8070-7062
  • Hernández-González, Fernanda
  • Grafia, Ignacio
  • Prieto-González, Sergio|||0000-0003-3179-597X
  • Narváez, Javier|||0000-0002-1614-8064
  • Trallero Araguás, Ernesto|||0000-0003-3365-4521
  • Selva O'Callaghan, Albert|||0000-0003-2823-9761
  • Gualillo, Oreste|||0000-0002-7154-1328
  • Castañeda, Santos|||0000-0002-7748-853X
  • Cavagna, Lorenzo|||0000-0003-3292-1528
  • Cifrián, José Manuel|||0000-0003-3682-0142
  • Gonzalez-Gay, MA.|||0000-0002-7924-7406
MUC5B rs35705950 (G/T) is strongly associated with idiopathic pulmonary fibrosis (IPF) and also contributes to the risk of interstitial lung disease (ILD) in rheumatoid arthritis (RA-ILD) and chronic hypersensitivity pneumonitis (CHP). Due to this, we evaluated the implication of MUC5B rs35705950 in antisynthetase syndrome (ASSD), a pathology characterised by a high ILD incidence. 160 patients with ASSD (142 with ILD associated with ASSD [ASSD-ILD+]), 232 with ILD unrelated to ASSD (comprising 161 IPF, 27 RA-ILD and 44 CHP) and 534 healthy controls were genotyped. MUC5B rs35705950 frequency did not significantly differ between ASSD-ILD+ patients and healthy controls nor when ASSD patients were stratified according to the presence/absence of anti Jo-1 antibodies or ILD. No significant differences in MUC5B rs35705950 were also observed in ASSD-ILD+ patients with a usual interstitial pneumonia (UIP) pattern when compared to those with a non-UIP pattern. However, a statistically significant decrease of MUC5B rs35705950 GT, TT and T frequencies in ASSD-ILD+ patients compared to patients with ILD unrelated to ASSD was observed. In summary, our study does not support a role of MUC5B rs35705950 in ASSD. It also indicates that there are genetic differences between ILD associated with and that unrelated to ASSD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Tocilizumab in visual involvement of giant cell arteritis, a multicenter study of 471 patients

  • Loricera, Javier|||0000-0003-4754-0277
  • Castañeda, Santos|||0000-0002-7748-853X
  • Moriano, Clara
  • Narváez, Javier|||0000-0002-1614-8064
  • Aldasoro, Vicente
  • Maiz, Olga|||0000-0003-2900-9511
  • Melero-González, Rafael|||0000-0002-7967-351X
  • Villa, Ignacio
  • Vela, Paloma|||0000-0001-8566-5172
  • Romero-Yuste, Susana
  • Callejas Rubio, Jose Luis|||0000-0002-1653-0087
  • Miguel, Eugenio de|||0000-0001-5146-1964
  • Galíndez Agirregoikoa, Eva
  • Sivera, Francisca|||0000-0002-3414-1667
  • Fernández-López, Jesús C.
  • Galisteo-Lencastre, Carlos|||0000-0003-3619-3185
  • Ferraz-Amaro, Iván|||0000-0003-0197-5267
  • Sánchez Martín, Julio
  • Sánchez Bilbao, Lara
  • Calderón-Goercke, Mónica
  • Casado, Alfonso
  • Hernández, José L.
  • Gonzalez-Gay, MA.|||0000-0002-7924-7406
  • Blanco, Ricardo|||0000-0003-2344-2285
Visual involvement is the most feared complication of giant cell arteritis (GCA). Information on the efficacy of tocilizumab (TCZ) for this complication is scarce and controversial. We assessed a wide series of GCA treated with TCZ, to evaluate its role in the prevention of new visual complications and its efficacy when this manifestation was already present before the initiation of TCZ. This is an observational multicenter study of patients with GCA treated with TCZ. Patients were divided into two subgroups according to the presence or absence of visual involvement before TCZ onset. Visual manifestations were classified into the following categories: transient visual loss (TVL), permanent visual loss (PVL), diplopia, and blurred vision. Four hundred seventy-one GCA patients (mean age, 74 ± 9 years) were treated with TCZ. Visual manifestations were observed in 122 cases (26%), of which 81 were present at TCZ onset: PVL (n = 60; unilateral/bilateral: 48/12), TVL (n = 17; unilateral/bilateral: 11/6), diplopia (n = 2), and blurred vision (n = 2). None of the patients without previous visual involvement or with TVL had new episodes after initiation of TCZ, while only 11 out of 60 (18%) patients with PVL experienced some improvement. The two patients with diplopia and one of the two patients with blurred vision improved. TCZ may have a protective effect against the development of visual complications or new episodes of TVL in GCA. However, once PVL was established, only a few patients improved.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Role of VEGF Polymorphisms in the Susceptibility and Severity of Interstitial Lung Disease

  • Remuzgo-Martínez, Sara
  • Genre, Fernanda
  • Pulito-Cueto, Verónica
  • Atienza-Mateo, Belén
  • Mora Cuesta, Víctor Manuel
  • Iturbe Fernández, David
  • Berastegui Garcia, Cristina
Biomarker; Interstitial lung disease; Vascular endothelial growth factor, Biomarcador; Malaltia pulmonar intersticial; Factor de creixement endotelial vascular, Biomarcador; Enfermedad pulmonar intersticial; Factor de crecimiento vascular endotelial, The search for biomarkers that can help to establish an early diagnosis and prognosis of interstitial lung disease (ILD) is of potential interest. VEGF polymorphisms have been implicated in the development of several lung disorders. Consequently, we assessed, for the first time, the role of VEGF polymorphisms in the susceptibility and severity of ILD. A total of 436 Caucasian ILD patients (244 with idiopathic interstitial pneumonias (IIPs) and 192 with non-IIP) and 536 ethnically-matched healthy controls were genotyped for VEGF rs833061, rs1570360, rs2010963, rs3025020, and rs3025039 polymorphisms by TaqMan assays. Pulmonary function tests were collected from all the patients. VEGF serum levels were determined by ELISA in a subgroup of patients. No VEGF genotype, allele, carrier, or haplotype differences were found between ILD patients and controls as well as between IIP and non-IIP patients. However, an association of rs1570360 with IIP in women and also with lung function in IIP patients was found. None of the VEGF polymorphisms were associated with VEGF levels. In conclusion, our results suggest that VEGF does not seem to play a relevant role in ILD, although rs1570360 may influence the severity of ILD in women and a worse outcome in IIP patients., This research was partially supported by a grant from Spanish Society of Pulmonology and Thoracic Surgery (SEPAR 474-2017). S.R.-M. was supported by funds of the RETICS Program (RD16/0012/0009) from the “Instituto de Salud Carlos III” (ISCIII), co-funded by the European Regional Development Fund. V.P.-C. was supported by a pre-doctoral grant from IDIVAL (PREVAL 18/01). B.A.-M. was recipient of a “López Albo” post-residency program funded by Servicio Cántabro de Salud. L.L.-G. was supported by funds from IDIVAL (INNVAL 20/06). O.G. was beneficiary of a grant funded by Xunta de Galicia, Consellería de Educación, Universidade e Formación Profesional and Consellería de Economía, Emprego e Industria (GAIN), GPC IN607B2019/10. R.L.-M. was a recipient of a Miguel Servet type I program fellowship from the ISCIII, co-funded by the ESF, “Investing in your future” (grant CP16/00033).